Ten years after its first win at the Public Value Award, COLDPLASMATECH is among the five “Startups of the Decade.” At the anniversary finals on November 5, 2026, in Leipzig, the company received a special recognition in the Quality of Life category. In addition, COLDPLASMATECH won the People’s Choice Award, which was decided by a live vote from guests in the Congress Hall at the Leipzig Zoo.
Quality of Life as a Measure
The laudatory speech particularly highlighted achievements in the care of patients with severe burn injuries and in the treatment of chronic wounds. The award thus recognizes the development of CPT® cold plasma therapy for large treatment areas into a scientifically validated care approach.
Wounds that are slow to heal can significantly impact the daily lives of those affected for a long time. CPT® cold plasma therapy opens up additional treatment options within existing care protocols. The CPT®cube activation device and the CPT®patch plasma film enable the application of cold plasma over large areas of the wound. This ionized gas has an antibacterial effect—even against multidrug-resistant pathogens—and stimulates the body’s own healing processes.
Ten Years of Development with a Social Impact
Since the first awards ceremony in 2016, approximately 2,000 applications have been received for the Public Value Award, which honors companies for their contribution to the common good. To mark the anniversary, about 60 finalists from previous years were eligible to reapply, including COLDPLASMATECH, the winner of the first edition.
“When we first honored the company in 2016, we were also recognizing a promise it had made to society. I have closely followed its development over the past ten years. Today, we can say: COLDPLASMATECH has kept that promise.”
Prof. Dr. Timo Meynhardt, a public value researcher at the HHL Leipzig Graduate School of Management and the University of St. Gallen, and president-elect of Witten/Herdecke University.
From Product to Technology Platform
Over the past ten years, the company has evolved from a regional manufacturer of a single product into an internationally active medical technology company. Today’s technology platform includes a range of services supported by a growing network of specialized centers of expertise. Insights gained from day-to-day treatment and specific questions from clinical partners are incorporated into the product’s ongoing development.
“Our goal for the next ten years: to offer even more patients with hard-to-treat wounds new prospects for healing and quality of life—especially in cases where established therapies have reached their limits.”
Dr. Carsten C. Mahrenholz, Managing Director and Co-Founder of COLDPLASMATECH GmbH
